Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · Real-Time Price · USD
31.38
+0.15 (0.48%)
At close: Jan 16, 2026, 4:00 PM EST
31.58
+0.20 (0.64%)
After-hours: Jan 16, 2026, 7:59 PM EST
Hims & Hers Health Stock Forecast
Stock Price Forecast
The 11 analysts that cover Hims & Hers Health stock have a consensus rating of "Hold" and an average price target of $43.82, which forecasts a 39.64% increase in the stock price over the next year. The lowest target is $30 and the highest is $85.
Price Target: $43.82 (+39.64%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Hims & Hers Health stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 7 | 7 | 8 | 8 | 7 | 8 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 11 | 11 | 12 | 12 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Hold Initiates $33 | Hold | Initiates | $33 | +5.16% | Jan 12, 2026 |
| Barclays | Barclays | Buy Initiates $48 | Buy | Initiates | $48 | +52.96% | Dec 9, 2025 |
| B of A Securities | B of A Securities | Sell Maintains $28 → $32 | Sell | Maintains | $28 → $32 | +1.98% | Nov 4, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $85 | Strong Buy | Reiterates | $85 | +170.87% | Nov 4, 2025 |
| Keybanc | Keybanc | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Oct 21, 2025 |
Financial Forecast
Revenue This Year
2.40B
from 1.48B
Increased by 62.27%
Revenue Next Year
2.83B
from 2.40B
Increased by 18.20%
EPS This Year
0.47
from 0.53
Decreased by -11.32%
EPS Next Year
0.60
from 0.47
Increased by 26.96%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.5B | 3.1B | ||||
| Avg | 2.4B | 2.8B | ||||
| Low | 2.3B | 2.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 68.6% | 30.8% | ||||
| Avg | 62.3% | 18.2% | ||||
| Low | 55.2% | 3.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 0.61 | 1.44 | ||
| Avg | 0.47 | 0.60 | ||
| Low | 0.26 | 0.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 14.4% | 204.8% | ||
| Avg | -11.3% | 27.0% | ||
| Low | -50.3% | -79.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.